Updated Oct 29, 10:32 PM · 60 sources analyzed
Key Takeaways
BMS terminated MORAb-202 Phase 2 in platinum-resistant ovarian cancer with no data disclosed, signaling a pipeline cut.
Three separate Phase 3 and Phase 2 programs — ravulizumab (ARTEMIS), BCX9930, and GEN1107 — were terminated with no efficacy data released.
AstraZeneca's genotype-selected NASH trial (AZD2693) and Bayer's finerenone Type 1 diabetes CKD study completed — data readouts are the next critical events.
🏆 Winner
Bayer — finerenone Phase 3 completion in Type 1 diabetes CKD opens a potential label expansion into an underserved population with no approved renal protective standard of care.
📉 Loser
Bristol-Myers Squibb — MORAb-202 Phase 2 termination in ovarian cancer removes an ADC asset from the pipeline with no clinical data to show for the investment.
🔭 Watch Next
Recursion Pharmaceuticals is expected to disclose Phase 2 results for REC-994 in cerebral cavernous malformation following study completion — a readout that will test whether its AI-driven discovery platform translates to clinical benefit.
BMS MORAb-202 Phase 2 terminated in platinum-resistant ovarian cancer
Bristol-Myers Squibb's Phase 2 trial of farletuzumab ecteribulin (MORAb-202) versus investigator's choice chemotherapy in platinum-resistant high-grade serous ovarian cancer has been terminated, according to a ClinicalTrials.gov status update. No efficacy or safety data have been released alongside the termination notice, leaving the reason for discontinuation unclear from the registry alone. The termination adds to a difficult competitive landscape for folate receptor-alpha targeted antibody-drug conjugates, a class that has seen both promise and setbacks in ovarian cancer.
ClinicalTrials.gov ↗Bristol-Myers Squibb
Farletuzumab ecteribulin (MORAb-202) in Platinum-resistant high-grade serous ovarian, primary peritoneal, or fallopian tube cancer
The trial was marked Terminated on ClinicalTrials.gov. Full efficacy and safety data have not been released, and no reason for termination is provided in the registry entry.
Why it matters
Without a disclosed rationale, investors should consider both efficacy failure and portfolio prioritization as possible drivers — BMS has been actively streamlining its oncology pipeline. The key question for the investment thesis is whether this reflects a drug-specific failure or a broader strategic retreat from the ADC space.
What to watch
Watch for any conference presentation or publication of MORAb-202 data that clarifies whether efficacy or safety drove the termination — likely at a major oncology meeting in H1 2027.
Genmab
GEN1107 (PRO1107) in Endometrial cancer, ovarian cancer, triple-negative breast cancer
The Phase 1/2 study of GEN1107 in advanced solid tumors was marked Terminated on ClinicalTrials.gov. No efficacy or safety data have been released alongside the termination.
Why it matters
Genmab's pipeline is deep enough to absorb a single early-stage termination, but the loss of a solid tumor asset in three high-interest indications warrants attention as the company works to diversify beyond its hematology franchise. Investors will want to understand whether this reflects a mechanistic issue or resource reallocation.
What to watch
Watch for Genmab's next pipeline update — expected at its annual R&D day — for any commentary on the GEN1107 termination rationale and how it redeployment resources across its solid tumor efforts.
Alexion Pharmaceuticals (AstraZeneca)
Ravulizumab in Cardiac surgery-associated acute kidney injury and major adverse kidney events (CSA-AKI / MAKE) in chronic kidney disease
The ARTEMIS Phase 3 trial evaluating a single IV dose of ravulizumab to reduce major adverse kidney events following cardiac surgery in CKD patients was marked Terminated on ClinicalTrials.gov. No efficacy or safety data have been disclosed.
Why it matters
Ravulizumab is already a blockbuster in PNH and aHUS; this termination does not threaten the core franchise, but it signals that perioperative kidney protection in CKD — a commercially attractive indication with no approved preventive therapy — remains an unmet need that will attract other complement-pathway competitors. Investors should watch whether AZ/Alexion revisits the indication with a different dosing strategy.
What to watch
Watch for any AstraZeneca R&D update clarifying whether the ARTEMIS termination reflects a futility finding, safety signal, or strategic deprioritization — an important distinction for modeling ravulizumab's addressable market.
Recursion Pharmaceuticals
REC-994 in Symptomatic cerebral cavernous malformation (CCM)
The randomized, double-blind, placebo-controlled Phase 2 trial of REC-994 (200 mg and 400 mg) in symptomatic CCM has been marked Completed on ClinicalTrials.gov. Full efficacy and safety data have not been released alongside the registry status update.
Why it matters
Recursion has positioned REC-994 as a proof-of-concept for its AI-driven drug discovery platform — a clean Phase 2 readout, positive or negative, will carry weight well beyond this single asset because it will test whether the platform's target identification translates to clinical benefit. The absence of disclosed data at completion is notable; the company's credibility depends on transparency here.
What to watch
Watch for Recursion to disclose Phase 2 results at a neurology meeting or via press release — timing is not specified, but data presentation is expected in the near term following study completion.
The trial was marked Terminated on ClinicalTrials.gov. Full efficacy and safety data have not been released, and no reason for termination is provided in the registry entry.
Why it matters
The termination removes a potential FRα-targeting ADC competitor from the ovarian cancer pipeline and raises questions about the mechanism's viability in this heavily pretreated setting.
Analysis
Without a disclosed rationale, investors should consider both efficacy failure and portfolio prioritization as possible drivers — BMS has been actively streamlining its oncology pipeline. The key question for the investment thesis is whether this reflects a drug-specific failure or a broader strategic retreat from the ADC space.
What to watch
Watch for any conference presentation or publication of MORAb-202 data that clarifies whether efficacy or safety drove the termination — likely at a major oncology meeting in H1 2027.
The Phase 1/2 study of GEN1107 in advanced solid tumors was marked Terminated on ClinicalTrials.gov. No efficacy or safety data have been released alongside the termination.
Why it matters
Genmab loses an early oncology asset in three gynecologic and breast tumor types, narrowing its solid tumor pipeline at a time when competition in these indications is intensifying.
Analysis
Genmab's pipeline is deep enough to absorb a single early-stage termination, but the loss of a solid tumor asset in three high-interest indications warrants attention as the company works to diversify beyond its hematology franchise. Investors will want to understand whether this reflects a mechanistic issue or resource reallocation.
What to watch
Watch for Genmab's next pipeline update — expected at its annual R&D day — for any commentary on the GEN1107 termination rationale and how it redeployment resources across its solid tumor efforts.
The ARTEMIS Phase 3 trial evaluating a single IV dose of ravulizumab to reduce major adverse kidney events following cardiac surgery in CKD patients was marked Terminated on ClinicalTrials.gov. No efficacy or safety data have been disclosed.
Why it matters
The termination closes off a potential new indication for ravulizumab (Ultomiris) beyond its approved complement-mediated disease portfolio, removing a meaningful revenue diversification opportunity.
Analysis
Ravulizumab is already a blockbuster in PNH and aHUS; this termination does not threaten the core franchise, but it signals that perioperative kidney protection in CKD — a commercially attractive indication with no approved preventive therapy — remains an unmet need that will attract other complement-pathway competitors. Investors should watch whether AZ/Alexion revisits the indication with a different dosing strategy.
What to watch
Watch for any AstraZeneca R&D update clarifying whether the ARTEMIS termination reflects a futility finding, safety signal, or strategic deprioritization — an important distinction for modeling ravulizumab's addressable market.
The randomized, double-blind, placebo-controlled Phase 2 trial of REC-994 (200 mg and 400 mg) in symptomatic CCM has been marked Completed on ClinicalTrials.gov. Full efficacy and safety data have not been released alongside the registry status update.
Why it matters
CCM is a rare neurological disease with no approved pharmacotherapy; a positive Phase 2 result would establish Recursion as the lead clinical-stage program in a well-defined genetic patient population.
Analysis
Recursion has positioned REC-994 as a proof-of-concept for its AI-driven drug discovery platform — a clean Phase 2 readout, positive or negative, will carry weight well beyond this single asset because it will test whether the platform's target identification translates to clinical benefit. The absence of disclosed data at completion is notable; the company's credibility depends on transparency here.
What to watch
Watch for Recursion to disclose Phase 2 results at a neurology meeting or via press release — timing is not specified, but data presentation is expected in the near term following study completion.
The Phase 2 monotherapy study of BCX9930 in complement inhibitor-naive PNH patients was marked Terminated on ClinicalTrials.gov. No efficacy or safety data are disclosed in the registry entry. BioCryst previously placed BCX9930 on clinical hold due to renal safety signals identified in 2022; this termination appears to be the formal close of that program.
Why it matters
The termination of BCX9930 ends BioCryst's complement franchise ambitions in PNH, ceding a competitive market to ravulizumab, iptacopan, and danicopan.
Analysis
BioCryst's PNH program was effectively dead following the 2022 renal safety signal; this registry update is the administrative confirmation. The investment thesis for BioCryst now rests almost entirely on berotralstat in hereditary angioedema — the company has no viable complement pathway asset to replace BCX9930.
What to watch
Watch BioCryst's berotralstat commercial trajectory and any pipeline update at its next earnings call for signals of whether the company is rebuilding its complement or rare disease pipeline.
Computationally guided design of novel PDE4 inhibitors for plaque psoriasis
Researchers used computational modeling to design two novel phosphodiesterase-4 (PDE4) inhibitors — enzymes that regulate inflammation — with structural profiles intended to improve upon current approved agents in plaque psoriasis.
Why it matters
If the computational designs show improved selectivity or reduced side effects (particularly nausea, a class-limiting issue for PDE4 inhibitors like apremilast) in subsequent in vitro and in vivo testing, this approach could accelerate lead optimization for next-generation topical or oral psoriasis therapies.
Analysis
PDE4 inhibition is a validated target in psoriasis, but the class is constrained by GI tolerability and, for topical agents, modest efficacy relative to biologics. A computationally guided design that addresses selectivity could reopen the oral small-molecule psoriasis space — a market dominated by IL-17 and IL-23 biologics but still price-sensitive. This is preprint-stage work with no clinical data; the distance to patient benefit remains large.
What to watch
Watch for follow-on experimental validation of these compounds in cell-based and animal models — the next meaningful milestone before any IND-enabling work could begin.
AstraZeneca AZD2693 Phase 2 completed in PNPLA3-genotyped NASH with fibrosis
AstraZeneca's Phase 2 trial of AZD2693 — an antisense therapy targeting a specific liver risk variant called PNPLA3 148M — in non-cirrhotic NASH with fibrosis reached completion status on ClinicalTrials.gov, representing one of the first genotype-selected NASH trials to finish.
Why it matters
Genotype-selected trial designs in NASH are scientifically compelling because the PNPLA3 148M variant is one of the best-validated genetic risk factors for liver disease progression; a clean Phase 2 dataset could validate precision patient selection as a path through the notoriously difficult NASH development landscape.
Analysis
AstraZeneca is betting that genetic stratification can rescue NASH drug development from the high Phase 3 failure rates that have plagued the field. Completion of this Phase 2 is a prerequisite for Phase 3 design decisions; the actual data readout — not yet disclosed — will determine whether the genotype-selection hypothesis holds clinically and whether AZD2693 can differentiate in a field now anchored by resmetirom's approval.
What to watch
Watch for AstraZeneca to present AZD2693 Phase 2 results at EASL or AASLD in 2027, which will determine whether the program advances to a genotype-enriched Phase 3.
Bayer finerenone Phase 3 completed in CKD plus Type 1 diabetes
Bayer's Phase 3 trial evaluating finerenone — a non-steroidal mineralocorticoid receptor antagonist (a drug class that blocks a hormone receptor involved in kidney and heart damage) — in chronic kidney disease patients with Type 1 diabetes reached completion on ClinicalTrials.gov.
Why it matters
Finerenone is already approved for CKD in Type 2 diabetes; a positive Phase 3 result in Type 1 diabetes would expand the addressable population and potentially set a new standard of care in a patient group with limited options for slowing CKD progression.
Analysis
Type 1 diabetic nephropathy is a distinct and underserved population — SGLT2 inhibitors have limited efficacy signals here and carry risk of diabetic ketoacidosis. If finerenone shows renal protection in this genotype, it meaningfully extends the franchise's commercial runway and positions Bayer ahead of any competing MRA programs still in earlier development. The data readout, not yet disclosed, is the pivotal event.
What to watch
Watch for Bayer to disclose finerenone Type 1 diabetes CKD results at ERA (European Renal Association) Congress or ASN Kidney Week 2027, which would frame any regulatory submission timeline.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
No coverage today
None of your tracked companies appeared in today's sources.